+

WO2006003965A1 - Compositions blanchissant la peau - Google Patents

Compositions blanchissant la peau Download PDF

Info

Publication number
WO2006003965A1
WO2006003965A1 PCT/JP2005/012025 JP2005012025W WO2006003965A1 WO 2006003965 A1 WO2006003965 A1 WO 2006003965A1 JP 2005012025 W JP2005012025 W JP 2005012025W WO 2006003965 A1 WO2006003965 A1 WO 2006003965A1
Authority
WO
WIPO (PCT)
Prior art keywords
salt
acid
extract
tranexamic acid
pantethine
Prior art date
Application number
PCT/JP2005/012025
Other languages
English (en)
Japanese (ja)
Inventor
Yoshinobu Morimoto
Asami Watake
Original Assignee
Daiichi Sankyo Healthcare Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Healthcare Co., Ltd. filed Critical Daiichi Sankyo Healthcare Co., Ltd.
Priority to JP2006528778A priority Critical patent/JPWO2006003965A1/ja
Publication of WO2006003965A1 publication Critical patent/WO2006003965A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0216—Solid or semisolid forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A61K8/447—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/676—Ascorbic acid, i.e. vitamin C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/004—Aftersun preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration

Definitions

  • the present invention relates to a novel composition, and more particularly to a whitening composition (whitening agent).
  • Pigmentation such as skin melanosis caused by drugs such as stains, freckles, sunburn, dark skin and steroids, is caused by excessive deposition of melanin pigment on the skin. It is a cytoplasmic granule melanoma in melanocytes. Tyrosine is oxidized by tyrosinase, biosynthesis of dopa and dopaquinone. Furthermore, dopaquinone is converted to indoquinone by auto-oxidation by ultraviolet rays, and melanin is produced through complicated pathways. It is known to be synthesized. Such pigmentation is particularly cosmetically favorable for women.
  • Patent Document 1 As a pigmentation prevention / treatment agent (whitening agent), L-ascorbic acid and its derivatives (see Patent Document 1), kojic acid (see Patent Document 2), L-cysteine (see Patent Document 3), arbutin ( Known are Patent Document 4), Arctostaphylos uva-ursi, an extract thereof (see Patent Document 5), a combination of tranexamic acid and ascorbic acid (Patent Document 6), and the like.
  • Patent Document 1 JP-A-49-86554
  • Patent Document 2 JP-A-53-3538
  • Patent Document 3 Japanese Patent Application Laid-Open No. 59-128320
  • Patent Document 4 Japanese Patent Application Laid-Open No. 60-56912
  • Patent Document 5 JP-A-6-166609
  • Patent Document 6 Japanese Patent Laid-Open No. 4-243825
  • the present invention provides a novel composition, specifically, a whitening composition (whitening agent) having an excellent effect. To do.
  • the present invention relates to the following.
  • a composition comprising (i) tranexamic acid or a salt thereof, and (ii) panthetins.
  • composition of (1) or (2) above for whitening agent, prevention of pigmentation and production of Z or therapeutic agent.
  • a whitening method characterized by administering an effective amount of (i) tranexamic acid or a salt thereof, and (ii) a panthetin, and a method for preventing and / or treating pigmentation.
  • a whitening method characterized by administering, and a prevention and Z or treatment of pigmentation.
  • composition of the present invention has an excellent melanin pigmentation inhibitory effect as described in Examples below. Therefore, the composition of the present invention can be used as a whitening composition (whitening agent), as well as for prevention of pigmentation such as skin darkening caused by drugs such as spots, freckles, sunburn, dark skin and steroids, and Z or Useful as a therapeutic composition.
  • whitening composition whitening agent
  • prevention of pigmentation such as skin darkening caused by drugs such as spots, freckles, sunburn, dark skin and steroids, and Z or Useful as a therapeutic composition.
  • Tranexamic acid (trans-4 aminomethylcyclohexanecarboxylic acid) or a salt thereof, which is useful in the present invention, is a known compound, and a commercially available product may be used as a method for obtaining the same. Can also be manufactured.
  • a salt of tranexamic acid List mineral salts such as hydrochloride, nitrate and sulfate, organic acid salts such as methanesulfonate, alkali metal salts such as sodium salt, potassium salt, calcium salt and magnesium salt, alkaline earth metal salts, etc. Can do.
  • tranexamic acid or a salt thereof is preferably tranexamic acid.
  • Panthetins include pantothenyl alcohol, pantothenyl ether, acetyl pantotenyl ether, benzoyl pantotenyl ether, dicarboethoxy pantothenic acid ethyl ester, nontethein, panthetin, phosphopanthetin, pantothenic acid And a salt of pantothenic acid.
  • pantothenic acid examples include mineral salts such as hydrochloride, nitrate and sulfate, alkali metal salts such as sodium salt, potassium salt, calcium salt and magnesium salt, and alkaline earth metal salt.
  • mineral salts such as hydrochloride, nitrate and sulfate
  • alkali metal salts such as sodium salt, potassium salt, calcium salt and magnesium salt
  • alkaline earth metal salt such as calcium salt, calcium salt and magnesium salt
  • alkaline earth metal salt alkaline earth metal salt.
  • pantethine, pantothenic acid, and pantothenic acid salt are preferred as pantetins
  • pantothenic acid salt calcium pantothenate is preferred.
  • L-cysteine, a derivative thereof, or a salt thereof that is useful in the present invention is a known compound, and as a method for obtaining the L-cysteine, a commercially available product may be used, or it can be produced based on a known method.
  • L-cysteine derivatives include N-acetyl-L-cysteine, L-homocistine, L-cysteic acid, L-homocysteic acid, L-cysteine sulfinic acid, S-sulfino-L L-cysteine, S-sulfo-L-cysteine, cystine (systemine). Dimer) and the like.
  • L-cysteine and its derivatives mineral salts such as hydrochloride, nitrate and sulfate, alkali metal salts such as sodium salt, potassium salt, calcium salt and magnesium salt, and alkaline earth metal salts and the like can be used. Can be mentioned.
  • L-cysteine is preferred as L-cysteine, a derivative thereof, or a salt thereof.
  • L-ascorbic acid, a derivative thereof or a salt thereof, which is useful in the present invention is a known compound, and a commercially available product may be used as a method for obtaining the product, or the production may be performed based on a known method. You can also.
  • mineral salts such as hydrochloride, nitrate, sulfate, sodium salt, potassium salt, calcium salt, magnesium Examples thereof include alkali metal salts such as salts and alkaline earth metal salts.
  • L-ascorbic acid its derivatives or salts thereof include L-ascorbic acid; L-ascorbate such as sodium L-ascorbate, magnesium L-ascorenolevate, potassium L-ascorenolate, calcium L-ascorbate; L-ascorbic acid monostearate Ascorbic acid monofatty acid esters such as Late, L-ascorbic acid monopalmitate, L-ascorbic acid monooleate; L-ascorbic acid difatty acid esters such as L-ascorbic acid distearate, L-ascorbic acid dinormitate, L-ascorbic acid dioleate; L-ascorbic acid trifatty acid esters such as acid tristearate, L-ascorbic acid tripalmitate, L-ascorbic acid trioleate; L-ascorbyl sulfate, L-ascorbi L-corcorbic acid sulfates such as sodium sulfate, potassium L-corcor
  • L-ascorbic acid, a derivative thereof, or a salt thereof is preferably L-ascorbic acid.
  • the whitening composition (whitening agent) of the present invention includes stains, freckles, sunburn, dark black, steroids, etc.
  • pigmentation diseases such as skin melanosis caused by drugs
  • V to be administered to a person.
  • composition of the present invention may further contain a component that exhibits a known whitening effect and a component that enhances the whitening effect.
  • these components include, for example, pyridoxine, derivatives thereof or salts thereof (pyridoxine; pyridoxine salts such as pyridoxine hydrochloride; pyridoxamine, pyridoxal, etc.), hydroquinone or derivatives thereof (nodroquinone; hydroquinone 1 J3-D-glucose ( Hydone quinone glycosides such as arbutin), dalcosamine or derivatives thereof (darcosamine; darcosamine esters such as acetyl darcosamine; darcosamine ethers such as glucosamine methyl ether), hinokitiol or its Derivatives (hinokitiol; hinokitiol glycosides such as hinokitiol darcoside) , Azelaic acid, derivatives thereof or salts thereof (
  • Coenzyme Q CoQ
  • Coenzyme Q CoQ
  • carotene carotene
  • Sacylglutathiones N, S Di Kutanoyl glutathione distearyl, N, S dipalmitoyl glutathione dicetyl and other N, S diacyl glutathione diesters, resorcinol or its derivatives (resorcinol; 4 n butyl resorcinol, 4-isoamylresorcinol, 4- Alkylated resorcinols such as cyclohexylresorcinol, 5-methylresorcinol; 4-chlororesorcinol, 4 -Halogenated resorcinol such as bromoresorcinol), glycogen, quincein or its extract, Hammamelis or its extract, yukinoshita or its extract, zinc or its extract, chia or its extract, itadori or its extraction , Melissa or extract thereof, Thyme or extract thereof, Strawberry or extract thereof, Seinokogi or extract thereof, Hypericum or extract thereof, Hypericum or
  • composition of the present invention may be administered orally or parenterally.
  • oral administration preparations include dosage forms such as tablets, capsules, powders, fine granules, liquids, troches, and jelly.
  • Formulation for parenteral administration Oral preparations include extract, plaster, spirit, suppository, suspension, tincture, ointment, poultice, liniment, lotion, aerosol, eye drop, injection, etc.
  • Parenteral preparations include dosage forms such as extracts, plasters, spirits, suspensions, tinctures, ointments, poultices, liniments, lotions, aerosols, etc. Is preferred.
  • the composition of the present invention is preferably an orally administered preparation (orally administered preparation).
  • the whitening composition of the present invention can also be in the form of a cosmetic composition such as lotion, cream, lotion, emulsion, foam, foundation, knocking agent, skin cleanser, shampoo, rinse, conditioner, etc. It is.
  • Formulation can be performed by a known formulation technique, and appropriate formulation additives can be added to the formulation.
  • Formulation additives include excipients, binders, disintegrants, lubricants, fluidizing agents, suspending agents, emulsifiers, stabilizers, moisturizing (wetting) agents, preservatives, solvents, solubilizing agents, Preservatives, flavoring agents, sweeteners, pigments, fragrances, propellants and the like can be mentioned, and the formulation additives are appropriately selected within the range without impairing the effects of the present invention, and an appropriate amount is added. .
  • the mixing ratio of (i) tranexamic acid or a salt thereof and (ii) panthetins may be appropriately determined and an appropriate mixing ratio may be determined.
  • i): (ii) l: 0.01 to 25 force S, preferably 1: 0.03: L 5 force S, more preferably 1: 0.08 to 0.12 force S
  • tranexamic acid or its salt preferably 1: 0.03: L 5 force S, more preferably 1: 0.08 to 0.12 force S
  • panthetin ascorbic acid, its derivative or their salt
  • L-ascorbic acid L-ascorbic acid, its derivative or their salt
  • the whitening composition (whitening agent) of the present invention is appropriately examined according to the sex, age, symptoms, administration (medication) method, frequency of administration (medication), administration (medication) time, etc.
  • the dosage (dose) can be determined.
  • tranexamic acid or a salt thereof is preferably administered (taken) in an amount of 50 to 2500 mg per day, more preferably 400 to 2000 mg (taken). It is preferable to administer (take) 30-1200 mg of pantethine. It is more preferable to administer (take) 60-6 OO mg.
  • L-cystine, its derivatives and These salts are preferably administered (taken) at 30 to 750 mg per day, more preferably 150-48 Omg (taken).
  • L-ascorbic acid, a derivative thereof or a salt thereof is preferably administered in an amount of 50 to 3000 mg (taken) per day, more preferably 300 to 2000 mg (taken).
  • the compounding amount thereof is 50-2500 mg of tranexamic acid or a salt thereof per day, and 30 pantetins. It is preferred to be formulated so that it will be administered (taken) up to 1200 mg. It is formulated so that 400-2000 mg of tranexamic acid or its salt per day and 60-600 mg of pantethine will be administered (taken). Things Force S More preferable.
  • whitening composition (whitening agent) of the present invention comprising tranexamic acid or a salt thereof, panthetins, L-cysteine, a derivative thereof or a salt thereof, and L-ascorbic acid, a derivative thereof or a salt thereof
  • Formulation amount is 50-2500 mg of tranexamic acid or its salt per day, 30-1200 mg of non-tetins, 30-750 mg of L-cysteine, its derivatives or their salts, and L-ascorbic acid, its derivatives or theirs It is preferable to formulate so that 50 to 3000 mg of salt will be administered (taken).
  • composition of the present invention may be manufactured as a single preparation containing all the components according to the present invention and administered (taken), or each component according to the present invention may be divided into separate preparations. It is also possible to make a kit preparation that allows these preparations to be administered (taken) simultaneously or sequentially!
  • UVB ultraviolet
  • UVB ultraviolet rays
  • UVB ultraviolet
  • a test specimen was prepared by dissolving in water for injection so that the following dosage was obtained.
  • Specimen (3) Tranexamic acid 375mgZkgZday + Panthetine 1200mgZkgZday Specimen (4): Tranexamic acid 1500mgZkgZday + Nontetin 1200mgZkgZday Specimen (5): Tranexamic acid 1500mgZkgZday + Nonthetin 1200mgZkgZday + L —Cystein 240mgZkgZday
  • UVB ultraviolet rays
  • Tablets were produced in the usual manner with the following composition (6 tablets per day).
  • composition of the present invention showed an excellent inhibitory effect on melanin pigmentation, as is clear in the examples. Therefore, the composition of the present invention can be used as a whitening composition (whitening agent), as well as for prevention of pigmentation such as skin darkening caused by drugs such as stains, freckles, sunburn, dark skin and steroids. It is useful as a therapeutic composition.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne des compositions servant au blanchiment de la peau ou à la prévention et/ou au traitement de mélanopathies lesquelles présentent une excellente efficacité vis-à-vis de mélanopathies telles que le mélasme, des taches de rousseur de type Ephelis, des coups de soleil, une peau foncée ou une mélanose provoquées par des médicaments tels que des stéroïdes. A savoir (1) une composition contenant (i) de l'acide tranexamique ou un sel de celui-ci (de préférence de l'acide tranexamique) et (ii) une pantethine (de préférence de la pantethine) ; et (2) une composition contenant (i) de l'acide tranexamique ou un sel de celui-ci (de préférence de l'acide tranexamique), (ii) une pantethine (de préférence de la pantethine), (iii) de la L-cystéine, un dérivé de celle-ci, un sel de l'un ou l'autre (de préférence de la L-cystéine) et (iv) de l'acide L-ascorbique, un dérivé de celui-ci ou un sel de l'un ou l'autre (de préférence de l'acide L-ascorbique).
PCT/JP2005/012025 2004-06-30 2005-06-30 Compositions blanchissant la peau WO2006003965A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2006528778A JPWO2006003965A1 (ja) 2004-06-30 2005-06-30 美白組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004192854 2004-06-30
JP2004-192854 2004-06-30

Publications (1)

Publication Number Publication Date
WO2006003965A1 true WO2006003965A1 (fr) 2006-01-12

Family

ID=35782773

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2005/012025 WO2006003965A1 (fr) 2004-06-30 2005-06-30 Compositions blanchissant la peau

Country Status (2)

Country Link
JP (1) JPWO2006003965A1 (fr)
WO (1) WO2006003965A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007269786A (ja) * 2006-03-09 2007-10-18 Daiichi Sankyo Healthcare Co Ltd パンテチン含有経口液剤
WO2010016509A1 (fr) * 2008-08-06 2010-02-11 第一三共ヘルスケア株式会社 Composition pharmaceutique stable contenant de l'aide tranexamique et de l'acide ascorbique
WO2010027010A1 (fr) * 2008-09-05 2010-03-11 第一三共ヘルスケア株式会社 Préparation pharmaceutique solide contenant des ingrédients actifs séparés par une frontière interne
JP2010159252A (ja) * 2008-12-12 2010-07-22 Daiichi Sankyo Healthcare Co Ltd メラノソーム輸送抑制剤及びその方法
WO2011030727A1 (fr) 2009-09-11 2011-03-17 第一ファインケミカル株式会社 Préparation externe contenant un esterphosphorique de pantéthine
EP2335697A4 (fr) * 2008-09-12 2011-08-17 Daiichi Sankyo Healthcare Co Préparation médicinale stable dont la modification de couleur est supprimée.
JP2012193174A (ja) * 2011-03-02 2012-10-11 Daiichi Sankyo Healthcare Co Ltd トラネキサム酸を含有する生体内のメイラード反応抑制剤組成物
JP2012211130A (ja) * 2011-03-23 2012-11-01 Daiichi Sankyo Healthcare Co Ltd 生体内のメイラード反応抑制剤またはＡＧＥｓ生成抑制剤

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5673012A (en) * 1979-11-20 1981-06-17 Pola Chem Ind Inc Beautifying cosmetic
JPH0193519A (ja) * 1987-10-02 1989-04-12 Shiseido Co Ltd 抗色素沈着外用剤
JPH02237906A (ja) * 1989-03-10 1990-09-20 Lion Corp 皮膚外用剤
JPH04243825A (ja) * 1991-01-25 1992-08-31 Ss Pharmaceut Co Ltd 色素沈着症治療剤
JPH05262660A (ja) * 1991-12-18 1993-10-12 Dai Ichi Seiyaku Co Ltd 三成分配合剤
JPH0680564A (ja) * 1992-09-03 1994-03-22 Meiji Seika Kaisha Ltd 抗色素沈着治療薬
JP2004091370A (ja) * 2002-08-30 2004-03-25 Taiyo Yakuhin Kogyo Kk 美白効果増強剤
JP2004091473A (ja) * 2002-07-12 2004-03-25 Tadayasu Takada 色素沈着改善治療薬
WO2004060364A1 (fr) * 2002-12-27 2004-07-22 Daiichi Pharmaceutical Co., Ltd. Composition eclaircissant la peau
JP2004331661A (ja) * 2003-04-16 2004-11-25 Dai Ichi Seiyaku Co Ltd 医薬組成物
JP2005194203A (ja) * 2003-12-26 2005-07-21 Dai Ichi Seiyaku Co Ltd 美白用組成物

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5673012A (en) * 1979-11-20 1981-06-17 Pola Chem Ind Inc Beautifying cosmetic
JPH0193519A (ja) * 1987-10-02 1989-04-12 Shiseido Co Ltd 抗色素沈着外用剤
JPH02237906A (ja) * 1989-03-10 1990-09-20 Lion Corp 皮膚外用剤
JPH04243825A (ja) * 1991-01-25 1992-08-31 Ss Pharmaceut Co Ltd 色素沈着症治療剤
JPH05262660A (ja) * 1991-12-18 1993-10-12 Dai Ichi Seiyaku Co Ltd 三成分配合剤
JPH0680564A (ja) * 1992-09-03 1994-03-22 Meiji Seika Kaisha Ltd 抗色素沈着治療薬
JP2004091473A (ja) * 2002-07-12 2004-03-25 Tadayasu Takada 色素沈着改善治療薬
JP2004091370A (ja) * 2002-08-30 2004-03-25 Taiyo Yakuhin Kogyo Kk 美白効果増強剤
WO2004060364A1 (fr) * 2002-12-27 2004-07-22 Daiichi Pharmaceutical Co., Ltd. Composition eclaircissant la peau
JP2004331661A (ja) * 2003-04-16 2004-11-25 Dai Ichi Seiyaku Co Ltd 医薬組成物
JP2005194203A (ja) * 2003-12-26 2005-07-21 Dai Ichi Seiyaku Co Ltd 美白用組成物

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007269786A (ja) * 2006-03-09 2007-10-18 Daiichi Sankyo Healthcare Co Ltd パンテチン含有経口液剤
WO2010016509A1 (fr) * 2008-08-06 2010-02-11 第一三共ヘルスケア株式会社 Composition pharmaceutique stable contenant de l'aide tranexamique et de l'acide ascorbique
JP5517938B2 (ja) * 2008-08-06 2014-06-11 第一三共ヘルスケア株式会社 安定なトラネキサム酸とアスコルビン酸含有医薬組成物
WO2010027010A1 (fr) * 2008-09-05 2010-03-11 第一三共ヘルスケア株式会社 Préparation pharmaceutique solide contenant des ingrédients actifs séparés par une frontière interne
JP5579066B2 (ja) * 2008-09-05 2014-08-27 第一三共ヘルスケア株式会社 有効成分が境界を有してなる医薬固形製剤
JP5498387B2 (ja) * 2008-09-12 2014-05-21 第一三共ヘルスケア株式会社 変色が抑制された安定な医薬製剤
EP2335697A4 (fr) * 2008-09-12 2011-08-17 Daiichi Sankyo Healthcare Co Préparation médicinale stable dont la modification de couleur est supprimée.
JP2010159252A (ja) * 2008-12-12 2010-07-22 Daiichi Sankyo Healthcare Co Ltd メラノソーム輸送抑制剤及びその方法
CN102596165A (zh) * 2009-09-11 2012-07-18 第一精密化学股份有限公司 含有泛硫乙胺磷酸酯的外用剂
WO2011030727A1 (fr) 2009-09-11 2011-03-17 第一ファインケミカル株式会社 Préparation externe contenant un esterphosphorique de pantéthine
JP2012193174A (ja) * 2011-03-02 2012-10-11 Daiichi Sankyo Healthcare Co Ltd トラネキサム酸を含有する生体内のメイラード反応抑制剤組成物
JP2012211130A (ja) * 2011-03-23 2012-11-01 Daiichi Sankyo Healthcare Co Ltd 生体内のメイラード反応抑制剤またはＡＧＥｓ生成抑制剤
JP2016130265A (ja) * 2011-03-23 2016-07-21 第一三共ヘルスケア株式会社 生体内のメイラード反応抑制剤またはＡＧＥｓ生成抑制剤

Also Published As

Publication number Publication date
JPWO2006003965A1 (ja) 2008-04-17

Similar Documents

Publication Publication Date Title
KR101107754B1 (ko) 색소 침착의 예방·치료용 조성물
CN102355884B (zh) 由晚期糖基化终末产物的蓄积引起的皮肤老化的预防、抑制或改善剂
JP2011504498A (ja) 局所美白化粧品組成物およびその使用方法
KR20150057921A (ko) 항염증 또는 피부 미백용 조성물
WO2012147861A1 (fr) Composition pour inhibition de la production d'endosérine-1 et composition pour promotion de la prolifération cellulaire
WO2009088109A1 (fr) Composition contenant de la diosgénine pour le blanchiment de la peau
WO2006003965A1 (fr) Compositions blanchissant la peau
US20040185069A1 (en) Hydroxycitric acid derivatives for body slimming and tone firming compositions
KR101863297B1 (ko) 클로로겐산 및 루틴 화합물을 유효성분으로 포함하는 피부 주름 예방 또는 개선용 조성물
JP2005314403A (ja) 新規美白用組成物
JP2004217655A (ja) 美白用組成物
ES2793232T3 (es) Composiciones cosméticas para el blanqueamiento de la piel
US20160297971A1 (en) Anti-angiogenesis agent, cosmetic, medicine, crystallized red pigment, composition, and food comprising extract or red pigment from saw palmetto fruit and method of producing thereof
JP2010132575A (ja) 美白剤およびその利用
JP5133645B2 (ja) セトラキサートを含有する美白剤
KR102263330B1 (ko) 식물 제형의 상승작용적 조합을 통한 트리글리세리드 합성의 억제를 위한 조성물 및 방법
JP5462504B2 (ja) 美白用組成物
JP2005194203A (ja) 美白用組成物
US20100061948A1 (en) Composition for skin whitening comprising artemisinine
JPWO2012098664A1 (ja) ３−ヒドロキシ−２−ピロンを含有する美白剤
US12171852B1 (en) Composition and methods for regulating melanogenesis
WO2010086736A2 (fr) Nouvelle utilisation de la combinaison de resvératrol et de cystéine et de ses dérivés
KR101648739B1 (ko) (4aS,5S,6R,8aS)-5-((R)-3-((((E)-3-(3,4-디하이드록시페닐)아크릴로일)옥실)메틸)-5-하이드록시펜틸)-5,6,8a-트리메틸-3,4,4a,5,6,7,8,8a-옥타하이드로나프탈렌-1-카복실릭엑시드 화합물을 유효성분으로 함유하는 피부 미백용 조성물 및 이의 용도
KR101573420B1 (ko) (3r)-5-[[(2r,3s,4r,5r,6s)-6-[2-(3,4-디하이드록시페닐)-5,7-디하이드록시-4-옥소-크로멘-8-일]-3,4,5-트리하이드록시-테트라하이드로피란-2-일]메톡시]-3-하이드록시-3-메틸-5-옥소-펜타노익엑시드 화합물을 유효성분으로 함유하는 피부 미백용 조성물 및 이의 용도
CN100434062C (zh) L-2-氧代硫氮杂戍环烷-4-羧酸及其酯类衍生物作为皮肤药妆品的应用

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006528778

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载